| __timestamp | Incyte Corporation | Madrigal Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 15746000 |
| Thursday, January 1, 2015 | 196614000 | 13392000 |
| Friday, January 1, 2016 | 303251000 | 9290000 |
| Sunday, January 1, 2017 | 366406000 | 7672000 |
| Monday, January 1, 2018 | 434407000 | 15293000 |
| Tuesday, January 1, 2019 | 468711000 | 22648000 |
| Wednesday, January 1, 2020 | 516922000 | 21864000 |
| Friday, January 1, 2021 | 739560000 | 37318000 |
| Saturday, January 1, 2022 | 1002140000 | 48130000 |
| Sunday, January 1, 2023 | 1161300000 | 108146000 |
| Monday, January 1, 2024 | 1242157000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Incyte Corporation and Madrigal Pharmaceuticals, Inc. have shown contrasting approaches to handling these costs. Incyte's SG&A expenses have surged by over 600%, peaking in 2023, reflecting their aggressive expansion and investment strategies. Meanwhile, Madrigal Pharmaceuticals has maintained a more conservative growth, with their SG&A expenses increasing by approximately 590% over the same period. This difference highlights Incyte's focus on scaling operations, while Madrigal appears to prioritize cost efficiency. As the pharmaceutical landscape evolves, these strategies will play a pivotal role in determining each company's market position and financial health.
Breaking Down SG&A Expenses: argenx SE vs Madrigal Pharmaceuticals, Inc.
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Sarepta Therapeutics, Inc. vs Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Madrigal Pharmaceuticals, Inc. and ImmunityBio, Inc.
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or MannKind Corporation
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.